Oddo BHF Asset Management Sas Invests $2.77 Million in IQVIA Holdings Inc. (NYSE:IQV)

Oddo BHF Asset Management Sas bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,695 shares of the medical research company's stock, valued at approximately $2,771,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its stake in shares of IQVIA by 702.9% in the second quarter. Blue Trust Inc. now owns 281 shares of the medical research company's stock worth $59,000 after purchasing an additional 246 shares during the last quarter. Gradient Investments LLC raised its holdings in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock valued at $9,600,000 after acquiring an additional 6,134 shares in the last quarter. Oakworth Capital Inc. boosted its holdings in IQVIA by 74.8% in the second quarter. Oakworth Capital Inc. now owns 638 shares of the medical research company's stock valued at $135,000 after acquiring an additional 273 shares in the last quarter. Raymond James & Associates increased its position in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Finally, Milestone Asset Management LLC raised its holdings in IQVIA by 15.0% in the 2nd quarter. Milestone Asset Management LLC now owns 1,716 shares of the medical research company's stock worth $363,000 after purchasing an additional 224 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of several research analyst reports. BTIG Research lowered their price objective on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a report on Friday, November 1st. Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $256.19.

IQVIA Stock Performance

Shares of IQV traded down $1.31 during trading hours on Friday, hitting $199.06. The stock had a trading volume of 1,161,543 shares, compared to its average volume of 1,186,062. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a fifty day moving average price of $212.24 and a 200 day moving average price of $224.23. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $36.13 billion, a PE ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.